DE69826735D1 - Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin - Google Patents

Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin

Info

Publication number
DE69826735D1
DE69826735D1 DE69826735T DE69826735T DE69826735D1 DE 69826735 D1 DE69826735 D1 DE 69826735D1 DE 69826735 T DE69826735 T DE 69826735T DE 69826735 T DE69826735 T DE 69826735T DE 69826735 D1 DE69826735 D1 DE 69826735D1
Authority
DE
Germany
Prior art keywords
diethylphosphonomethoxy
adenine
ethyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826735T
Other languages
English (en)
Other versions
DE69826735T2 (de
Inventor
Murty N Arimilli
T K Lee
Lawrence V Manes
John D Munger
Ernest J Prisbe
M Schultze
Daphne E Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26732226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69826735(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of DE69826735D1 publication Critical patent/DE69826735D1/de
Application granted granted Critical
Publication of DE69826735T2 publication Critical patent/DE69826735T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transplanting Machines (AREA)
DE69826735T 1997-07-25 1998-07-23 Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin Expired - Lifetime DE69826735T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5377197P 1997-07-25 1997-07-25
US90074597A 1997-07-25 1997-07-25
US900745 1997-07-25
US53771P 1997-07-25

Publications (2)

Publication Number Publication Date
DE69826735D1 true DE69826735D1 (de) 2004-11-04
DE69826735T2 DE69826735T2 (de) 2005-10-06

Family

ID=26732226

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69826735T Expired - Lifetime DE69826735T2 (de) 1997-07-25 1998-07-23 Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin
DE69826734T Expired - Lifetime DE69826734T2 (de) 1997-07-25 1998-07-23 Verfahren zur Herstellung von Adefovir Dipivoxil
DE69809749T Expired - Lifetime DE69809749T2 (de) 1997-07-25 1998-07-23 Nukleotid-analoge zusammensetzung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69826734T Expired - Lifetime DE69826734T2 (de) 1997-07-25 1998-07-23 Verfahren zur Herstellung von Adefovir Dipivoxil
DE69809749T Expired - Lifetime DE69809749T2 (de) 1997-07-25 1998-07-23 Nukleotid-analoge zusammensetzung

Country Status (24)

Country Link
EP (1) EP0996430B1 (de)
JP (4) JP3573713B2 (de)
KR (3) KR100700089B1 (de)
CN (2) CN1274700C (de)
AR (1) AR016548A1 (de)
AT (3) ATE277937T1 (de)
AU (1) AU747163B2 (de)
BR (1) BR9811552A (de)
CA (3) CA2596320C (de)
CO (1) CO4980869A1 (de)
DE (3) DE69826735T2 (de)
DK (1) DK0996430T3 (de)
ES (3) ES2229029T3 (de)
HK (5) HK1046357B (de)
ID (1) ID28006A (de)
IL (1) IL133461A (de)
IN (1) IN190037B (de)
MY (1) MY129451A (de)
NZ (1) NZ501659A (de)
PT (3) PT1256585E (de)
SI (2) SI1256584T1 (de)
TR (3) TR200200137T2 (de)
TW (1) TW584635B (de)
WO (1) WO1999004774A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826735T2 (de) * 1997-07-25 2005-10-06 Gilead Sciences, Inc., Foster City Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
ES2536972T5 (es) 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
WO2004037161A2 (en) 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
US7417036B2 (en) 2002-11-12 2008-08-26 Tianjin Kinsly Pharmaceutical Co. Ltd. Crystal form of adefovir dipivoxil and its preparation
CN100383149C (zh) * 2002-11-12 2008-04-23 天津帝士力投资控股集团有限公司 一种新的晶状埃地双酯及其组合物
CN1303089C (zh) * 2002-11-19 2007-03-07 天津药物研究院 阿德福韦酯结晶形态及其制备方法
CN100415756C (zh) * 2003-10-14 2008-09-03 沈阳药科大学 草酸阿地福韦酯及其晶型和制备方法及用途
CN100358907C (zh) * 2004-03-31 2008-01-02 河北医科大学生物医学工程中心 一种非晶状阿德福韦酯的制备方法
CN100374118C (zh) * 2004-05-20 2008-03-12 江苏吴中中药研发有限公司 含有阿德福韦酯的滴丸剂及其制备方法
KR20070029196A (ko) 2004-06-08 2007-03-13 메타베이시스 테라퓨틱스, 인크. 고리 에스테르의 루이스 산 매개 합성
CN102240295B (zh) * 2005-06-13 2013-04-03 博瑞生物医药技术(苏州)有限公司 泰诺福韦衍生物及用途
CN100395248C (zh) * 2006-05-26 2008-06-18 华东理工大学 一种9-(二乙氧基磷酰基甲氧基乙基)-腺嘌啉的制备方法
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101343290B (zh) * 2008-05-24 2011-02-02 广东肇庆星湖生物科技股份有限公司 一种阿德福韦酯无水结晶物的制备方法、所得的阿德福韦酯无水结晶物及其应用
WO2010005195A2 (ko) * 2008-07-07 2010-01-14 (주)아모레퍼시픽 아데포버 디피복실의 결정형 ｌ의 제조방법
KR20100031045A (ko) 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
WO2010032958A2 (ko) 2008-09-17 2010-03-25 씨제이제일제당 (주) 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법
KR20100032803A (ko) 2008-09-18 2010-03-26 씨제이제일제당 (주) 아데포비어디피복실의 개선된 제조방법
KR20100061401A (ko) * 2008-11-28 2010-06-07 (주)아모레퍼시픽 아데포버 디피복실의 결정형, 그 제조방법 및 그를 포함하는 약제학적 조성물
EP2411392B1 (de) * 2009-03-26 2014-02-26 Daewoong Pharmaceutical Co., Ltd. Neue kristallformen von adefovirdipivoxil und verfahren zu deren herstellung
KR20100113302A (ko) * 2009-04-13 2010-10-21 한미홀딩스 주식회사 결정형 아데포비어 디피복실의 제조방법 및 이에 사용되는 아데포비어 디피복실 부탄올레이트
KR101528754B1 (ko) * 2009-04-14 2015-06-17 중앙대학교 산학협력단 신규한 복합결정형의 화합물, 그 제조방법 및 이를 포함하는 약제학적 조성물
KR100971486B1 (ko) * 2009-06-11 2010-07-21 주식회사 셀트리온화학연구소 아데포비어 다이피복실 말론산염 및 이를 포함하는 약제학적 조성물
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
WO2011016611A2 (ko) * 2009-08-03 2011-02-10 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 ｂ형 간염의 예방 또는 치료용 조성물
KR101129575B1 (ko) * 2009-09-02 2012-03-28 경희대학교 산학협력단 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
KR101048024B1 (ko) * 2009-10-09 2011-07-13 주식회사 삼오제약 9-(2-포스포닐메톡시에틸)아데닌, 아데포비아 디피복실 및 무정형 아데포비아 디피복실의 제조방법
EP2343056A1 (de) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Herstellung einer stabilen festen Dispersion von amorphem Adefovir dipivoxil
WO2012032541A1 (en) * 2010-09-06 2012-03-15 Matrix Laboratories Ltd "adefovir dipivoxil pseudopolymorph"
WO2012062835A1 (en) 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
CN102250146A (zh) * 2011-05-27 2011-11-23 扬州三友合成化工有限公司 抗乙肝药物阿德福韦的一种合成方法
KR101357687B1 (ko) * 2011-11-25 2014-02-05 숭실대학교산학협력단 고분자 첨가제를 이용한 아데포비어 디피복실 복합체의 결정입자 제어방법 및 이의 응용
KR101258678B1 (ko) 2012-02-29 2013-04-26 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 β형 간염의 예방 또는 치료용 조성물
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN102816184B (zh) * 2012-09-07 2015-11-18 山东大学 (2-(2-氧基-4-硫代嘧啶)乙氧基)甲基膦酸酯类衍生物及其制备与应用
CN103709198A (zh) * 2012-09-28 2014-04-09 江苏天士力帝益药业有限公司 一种阿德福韦酯的结晶方法
CN103333208B (zh) * 2013-06-04 2016-05-11 广州晶莱医药科技有限公司 阿德福韦酯马来酸盐及其制备方法和组合物
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3372227A1 (de) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablettenformulierung von adefovir dipivoxil
EP3737676B1 (de) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetalverbindungen und therapeutische verwendungen davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
ATE199906T1 (de) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
CA2261619C (en) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
DE69826735T2 (de) * 1997-07-25 2005-10-06 Gilead Sciences, Inc., Foster City Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin

Also Published As

Publication number Publication date
TR200000224T2 (tr) 2000-07-21
ID28006A (id) 2001-05-03
DE69826734T2 (de) 2005-10-06
HK1046357A1 (en) 2003-01-10
ATE228357T1 (de) 2002-12-15
HK1091211A1 (en) 2007-01-12
ATE277936T1 (de) 2004-10-15
JP2009263389A (ja) 2009-11-12
DE69809749T2 (de) 2003-09-11
SI1256585T1 (en) 2005-02-28
HK1051694A1 (en) 2003-08-15
CA2298057A1 (en) 1999-02-04
HK1051693A1 (en) 2003-08-15
AU747163B2 (en) 2002-05-09
PT996430E (pt) 2003-03-31
EP0996430B1 (de) 2002-11-27
JP2001512712A (ja) 2001-08-28
BR9811552A (pt) 2000-08-29
KR100700087B1 (ko) 2007-03-28
TW584635B (en) 2004-04-21
CA2596320C (en) 2008-12-23
ATE277937T1 (de) 2004-10-15
AR016548A1 (es) 2001-07-25
HK1046357B (zh) 2007-08-24
TR200200137T2 (tr) 2002-09-23
MY129451A (en) 2007-04-30
WO1999004774A2 (en) 1999-02-04
CA2298057C (en) 2008-11-18
PT1256584E (pt) 2004-12-31
JP4452034B2 (ja) 2010-04-21
CN1347695A (zh) 2002-05-08
KR100700089B1 (ko) 2007-03-28
ES2229029T3 (es) 2005-04-16
CN1251592A (zh) 2000-04-26
EP0996430A2 (de) 2000-05-03
DE69826734D1 (de) 2004-11-04
DE69809749D1 (de) 2003-01-09
NZ501659A (en) 2004-12-24
JP2005306879A (ja) 2005-11-04
ES2229030T3 (es) 2005-04-16
HK1091212A1 (en) 2007-01-12
CO4980869A1 (es) 2000-11-27
KR100618663B1 (ko) 2006-09-08
CA2596320A1 (en) 1999-02-04
CN1274700C (zh) 2006-09-13
ES2187991T3 (es) 2003-06-16
IL133461A (en) 2005-05-17
DE69826735T2 (de) 2005-10-06
CA2596497A1 (en) 1999-02-04
KR20010014284A (ko) 2001-02-26
TR200200117T2 (tr) 2002-06-21
PT1256585E (pt) 2005-01-31
WO1999004774A3 (en) 1999-04-15
IL133461A0 (en) 2001-04-30
KR20060038364A (ko) 2006-05-03
KR20060038363A (ko) 2006-05-03
CN1216062C (zh) 2005-08-24
AU8660998A (en) 1999-02-16
IN190037B (de) 2003-05-31
DK0996430T3 (da) 2003-03-10
JP2003342283A (ja) 2003-12-03
CA2596497C (en) 2008-12-23
JP3573713B2 (ja) 2004-10-06
SI1256584T1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
DE69826735D1 (de) Verfahren zur Herstellung von 9-(2-(diethylphosphonomethoxy)ethyl)-adenin
DE69835366D1 (de) Verfahren zur herstellung von perfluorvinylethersulfonsäure-derivaten
DE69822960D1 (de) Verfahren zur Herstellung von L-Leucin
DE69526182D1 (de) Verfahren zur Herstellung von Trehalosederivaten
DE69619067D1 (de) Verfahren zur Herstellung von 3-Amino-2-oxo-1-Halogenpropan-Derivaten
DE59603916D1 (de) Verfahren zur Herstellung von Imidazo-Benzodiazepin-Derivaten
DE69625253D1 (de) Verfahren zur Herstellung von Imidazochinazolinon-Derivaten
DE69615591D1 (de) Verfahren zur Herstellung von Purinderivaten
DE69635421D1 (de) Verfahren zur herstellung von 2-chlorthiazolderivaten
DE69830274D1 (de) Verfahren zur Herstellung von Fluorkohlenwasserstoffen
DE69708271D1 (de) Verfahren zur Herstellung von Benzolderivaten
DE69837100D1 (de) Verfahren zur herstellung von chinolinderivaten
DE69805887D1 (de) Verfahren zur Herstellung von alpha-Bromolactamderivaten
DE59813598D1 (de) Enzymatisches Verfahren zur Herstellung von (S)-Cyanhydrinen
DE69811598D1 (de) Verfahren zur Herstellung von Triphendioxazinverbindungen
DE59713017D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE69806876T2 (de) Verfahren zur Herstellung von 2-Chlorprop-1-en
DE69802470T2 (de) Verfahren zur Herstellung von halogenierten o-Hydroxydiphenylverbindungen
DE69836756D1 (de) Verfahren zur herstellung von xylitol
DE69810718T2 (de) Verfahren zur Herstellung von Benzoxazinen
DE59802385D1 (de) Verfahren zur Herstellung von N-Alkylcarbazolen
DE69826946D1 (de) Verfahren zur Herstellung von cis-Hexahydroisoindolinen
DE69807409T2 (de) Verfahren zur Herstellung von 7-Octen-1-al
DE69801350D1 (de) Verfahren zur Herstellung von Diacetoxybuten
DE59804868D1 (de) Verfahren zur Herstellung von substituierten Anthrachinonen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition